



NIH PUBLIC ACCESS

Author Manuscript

Aliment Pharmacol Ther. Author manuscript; available in PMC 2012 January 1.

Published in final edited form as:

Aliment Pharmacol Ther. 2011 January ; 33(2): 251–260. doi:10.1111/j.1365-2036.2010.04513.x.

Longitudinal Direct Medical Costs Associated with Constipation in Women

Rok Seon Choung, MD¹, Megan E. Branda², Denesh Chitkara, MD³, Nilay Shah, PhD², Slavica K. Katusic, MD², G. Richard Locke III, MD¹, and Nicholas J. Talley, MD, PhD⁴¹Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA²Department of Health Sciences Research; Mayo Clinic, Rochester, MN, USA³UNC Center for Functional GI and Motility Disorders, Chapel Hill, NC, USA⁴Department of Medicine, Mayo Clinic, Jacksonville, FL, USA

Abstract

Background—Although direct medical costs for constipation related medical visits are thought to be high, to date there have been no studies examining longitudinal resource utilization in adults with constipation.

Aim—To estimate the incremental direct medical costs associated with constipation in women.

Methods—This is a nested case-control study. The study population consisted of all mothers of 5,718 children in the population-based birth cohort born during 1976-1982 in a community. The cases presented to the medical facilities with constipation. The controls were randomly selected and matched to cases in a 2:1 ratio. Direct medical costs for constipated women and controls were collected for the years 1987-2002.

Results—We identified 168 women with a diagnosis of constipation. The total direct medical costs over a 15-year period for constipated subjects were more than double those of controls (\$63,591 [95% CI: 49,786- 81,396]) vs. \$24,529 [95% CI: 20,667-29,260]). The overall outpatient costs for constipated women were \$38,897 (95% CI: 31,381-48,253) compared to \$15,110 (95% CI: 12,904-17,781) for controls. The median annual outpatient visits for constipated women was 0.16 compared to 0.11 for controls.

Conclusion—Women with constipation have significantly higher medical care utilization and expenditures compared to women without constipation.

Keywords

chronic constipation; direct costs; case-control study

Corresponding Author: G. Richard Locke, III, M.D., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, Phone: 507-538-7637; Fax: 507-538-5820, locke.giles@mayo.edu.

Disclosures: No conflict of interest to disclose for all authors.

Specific Author Contributions: Rok Seon Choung, Denesh Chitkara, Nilay D. Shah, G. Richard Locke III, and Nicholas J. Talley participated in the design, analysis, and writing of the manuscript. Slavica K. Katusic participated in acquisition of the data and material support. Nilay Shah and Megan E. Branda provided the statistical analysis and assisted in writing the manuscript.

Writing Assistance: None

Introduction

Constipation is a chronic and common disorder, which presents as difficult, infrequent stool passage or a feeling of incomplete evacuation.¹⁻³ The prevalence of constipation from population-based studies in North America has been estimated to be as high as 27% in adults, depending on definition, demographic factors, and sampling.¹⁻⁷ In a systemic review of the burden of digestive diseases in the United States (U.S.) using a national database in 2004,⁸ Everhart et al. showed that constipation was the second most common ambulatory care diagnosis (6.3 million visits) among digestive diseases, after gastroesophageal reflux disease.

The evidence suggests that many patients have constipation-associated symptoms on a long-term basis.^{9, 10} Johanson and Kralstein⁹ reported that about 70% patients had constipation for more than two years using the web-based survey of the Knowledge Networks Panel. Talley et al.¹⁰ determined that in the general population, 89% of adults surveyed reported no change in their gastrointestinal symptoms during an intervening 12-20 month period. Thus, constipated subjects may present repeatedly for constipation over a prolonged period of time, which would likely contribute to an increased number of outpatient visits, diagnostic evaluations, and inpatient admissions. Although direct medical costs for constipation-related medical visits are thought to be high, to date there is no study examining longitudinal resource utilization in adults with constipation. The majority of studies, in fact, have relied on cross sectional medical costs for constipation.^{8, 11, 12} Sonnenberg et al.¹² estimated that visits for constipation resulted in costs of \$29 million (1985 value) for ambulatory visits. In a recent review,⁸ Everhart et al. estimated that in the U.S., the direct cost for constipation was \$1.6 billion in 2004 (using the Verispan database).

In order to accurately estimate the longitudinal medical costs of a particular disease or disorder, a large well-defined cohort with a long duration of follow up as well as direct data on the medical costs is required. However, many longitudinal cohorts including the Framingham Heart Study¹³ and Nurses' Health Study¹⁴ do not have information on medical resource utilization or economic costs. The Rochester Epidemiology Project (REP) has captured all diagnoses and procedures of residents in a local community since 1966.^{15, 16} Using the REP, we created a birth cohort¹⁷⁻¹⁹ which consisted of all children born from 1976 and 1982 to mothers who were residents of the community; we have previously reported that the incidence of constipation in children in this birth cohort was 3.9 per 1000 person-years, and children with constipation at an early age repeatedly presented for medical visits due to constipation.¹⁹ The aim of the present study was to estimate incremental direct medical costs and type of health care associated with constipation in women over a prolonged period of time in a community.

Methods

Setting

Olmsted County, Minnesota, is a metropolitan and rural area 90 miles southeast of Minneapolis, Minnesota. Census data from the 1990 population, representing the years the children from this birth cohort were in school, indicated the population was 70,745 (75% were age <45 years), and estimated to be 96% Caucasian; sociodemographically, the community is similar to the U.S. Caucasian population.^{15, 16} Over 95% of county residents receive their medical care from one of the two group practices in the community (Mayo Clinic and Olmsted Medical Center). Mayo Clinic has maintained a common medical record system with its two affiliated hospitals (Saint Marys and Rochester Methodist) for over 90 years.^{15, 16} Recorded diagnoses and surgical procedures are indexed, including the diagnoses made for outpatients seen in office or clinic consultations, emergency room visits

or nursing home care, as well as the diagnoses recorded for hospital inpatients, at autopsy examination or on death certificates. This system was further developed by the REP, which created similar indices for the records of other providers of medical care to local residents, most notably the Olmsted Medical Group and its affiliated Olmsted Community Hospital. Thus, details of the medical care provided to the residents of Olmsted County are available for study. Annually, over 80% of the entire population is attended by one or both of these two practices, and nearly everyone is seen at least once during any given three-year period.¹⁵ Therefore, the REP medical records linkage system also provides what is essentially an enumeration of the population from which samples can be drawn.

Study subjects from the 1976-1982 Rochester Birth Cohort

A cohort of all women who were residents of Rochester, Minnesota and who had children born between January 1, 1976 and December 31, 1982, was utilized. As approved by the Institutional Review Boards of the Mayo Clinic and Olmsted Medical Center, we used this system previously to draw the birth cohort which consisted of all children born between 1976 and 1982, to mothers residing in Olmsted County, Minnesota, comprising the Minnesota Independent School District 535 (n= 8548) in the city of Rochester.¹⁷⁻¹⁹ Subjects were identified through computerized birth certificate information from the Minnesota Department of Health, Division of Vital Statistics. The target population for this study consisted of 4075 women, not actively denying research authorization, whose children at or after the age of 5 years all still lived in Rochester. The women's length of follow-up was confirmed utilizing the REP.

Identification of cases with constipation

Through the REP, all diagnoses and surgical procedures recorded at Rochester medical facilities are indexed continuously for automated retrieval. This diagnostic index expedites retrieval of the unit (or dossier) medical record, which includes the history of all encounters in the hospital, community and ambulatory medical and social services, emergency department, outpatient clinics, and home visits, as well as laboratory and psychologic test results from birth until patients no longer reside within the community.

Case and control ascertainment

Constipation Cases: The cases included mothers who presented to Olmsted County medical facilities with constipation from the birth cohort. All mothers diagnosed with constipation were identified by using the diagnostic index developed by the REP. The constipation cases were identified as having one or more of the following diagnostic or surgical codes: constipation, H-ICDA-8 (Hospital Adaptation of the International Classification of Diseases) 05640112 or ICD-9 564; obstipation, H-ICDA-8 05640111; constipation (functional), ICD-0 564.9. The diagnostic index was designed to be sensitive and thus this search should capture all clinically diagnosed cases.

Controls: For each identified and reviewed case, we randomly selected two age-matched controls from the pool of mothers in the birth cohort who did not meet the constipation definition; that is, did not have one of the relevant HICDA or ICD-9 diagnoses for constipation. Thus, the controls were matched to cases in a 2:1 ratio, matching on age and years of follow-up.

Cost and Utilization Data

Beginning in January 1987, resource use and associated charges data from Mayo Clinic and Olmsted Medical Center were collected. This claims-based database contains information on medical resource utilization, associated charges, and estimated economic costs for patients

receiving care at either the Olmsted Medical Group or the Mayo Clinic and their associated inpatient facilities. The Olmsted County Healthcare Expenditure and Utilization Database (OCHEUD) provides a standardized inflation-adjusted estimate of costs for each service or procedure provided locally in constant dollars. Specifically, using a “bottom-up” (also referred to as micro-costing) costing approach, OCHEUD groups resource utilization into the Medicare Part A and B classification system. Part A billed charges are adjusted by using hospital cost-to-charge ratios and Part B physician services are valued by using Medicare reimbursement rates.

Although the services provided represent the clinical practice patterns of Mayo Clinic and Olmsted Medical Center providers, the value of each unit of service has been adjusted to national norms by use of widely accepted valuation techniques.²⁰ OCHEUD provides an estimated economic cost for each line item in the billing record and allows the aggregation of costs into categories deemed relevant to a particular study.²⁰

Data collection—Techniques for data collection have been previously described.^{18, 19, 21} Detailed sociodemographic factors were collected at birth in the 1976-1982 birth cohort. To determine factors that may influence medical presentation for a condition, birth certificate information was evaluated.

For the selected comorbidities status in the cases and controls, comorbidities were defined as an occurrence of at least one diagnosis within the time frame of the study. The diagnostic or surgical codes (Table 1) were selected based on our *a priori* expectation that they could have an impact on constipation status and medical costs, and were prevalent in the population.

Statistical Analyses

Descriptive statistics on baseline factors (e.g. age, gender, proportion of cesarean births, etc.) as well as sociodemographic factors are presented as means with standard deviations or frequencies with percentages. All categorical descriptive variables were compared using the Chi-square test statistic or Fisher's exact when appropriate. Continuous variables were compared using the Wilcoxon rank sum test. The unadjusted mean cost per year is presented for descriptive purposes only, as is the interquartile range and the range per patient per year for the entire time frame.

The effect of constipation on total costs during a given year on all women was assessed using two-part models to account for the zero values during a given year.²² For the two-part model specifications, logistic regression was used in part 1 to estimate the probability of costs conditional on patient characteristics; part 2 was employed with an inverse Gaussian distribution function with log link in cost models. Confidence intervals of estimated costs were generated by bootstrapping method.²³ Three time frames were chosen and adjusted by comorbid conditions. The only comorbid conditions that were counted were those that had been found within the given year or previous to the year being analyzed.

The Tian and Huang²⁴ method was used to assess the overall mean estimated costs. It is a two-part model for censored medical costs. The first part assumes a parametric model, in this case logistic regression for the probability of having a positive cost over 15 years with covariates. The second part uses a linear regression model for the positive costs. The censoring caused by incomplete follow up is addressed by applying the inverse probability weighting method to the two part model. This method allows for testing to see if a covariate has any effect on the total medical costs as well an estimation of the mean medical costs for individuals.

Similarly, this two-part model was employed to evaluate the predictors of costs within a multivariate model for those patients with constipation. Each comorbid condition that contained measurable counts was entered into the model predicting outpatient and total costs. For each variable entered into the model, an estimate of the percentage change in costs associated with each clinical characteristic is generated, contingent upon whether patients have positive costs. However, 4 (2.4%) patients did not have a positive value for total costs in the cohort, and 4 (2.4%) had no outpatient costs.

All calculated p-values were two-sided and p-values less than 0.05 were considered statistically significant. Statistical analyses was performed using SAS (SAS Institute, Cary, NC) and R - General (R Development core Team [2008]) software packages.²⁵

Results

A total of 4075 women were eligible for this study. Among the women who did not deny research authorization, a total of 168 subjects with a medical diagnosis of constipation were identified. The mean age of cases when medical costs were first available was 33.2 years (± 5.7), and the mean age of controls was 33.2 years (± 5.7) (table 2).

Table 2 summarizes the sociodemographic characteristics and comorbid conditions in constipated women and controls. There were no significant differences between sociodemographic comparisons such as education level, proportion with cesarean delivery, complications of delivery, legitimate births, or prenatal visits.

Medical visits and comorbid conditions

Annual medical visits and comorbid conditions of constipated women between 1987 and 2002 versus controls are summarized in Table 3. Cases used more of all types of medical services than their matched controls. Emergency department visits were the most frequently used type of services by constipated subjects, followed by outpatient care and inpatient care. In addition, more constipated women used hospital outpatient and inpatient care and the emergency department compared with controls. Notably, the mean annual number of emergency department visits for constipated women were 0.24 compared to 0.15 for controls ($p < 0.0001$) (Table 3). Interestingly, 15.5 % of constipated subjects received no medical diagnosis for one of the selected comorbid conditions compared with 33.6% of the matched controls ($p < .0001$) (Table 3). Moreover, constipated women were more likely to present for co-morbid abdominal pain, as well as somatic and psychological conditions during the 15-year period.

Estimated direct medical costs and comorbid conditions

The medical costs over the entire time period for cases (\$63,591 [95% CI: 49,786- 81,396]) were more than double those of controls (\$24,529 [95% CI: 20,667-29,260]) for the total direct medical costs over 15-year period. The overall outpatient costs for constipated women were also more than double those of controls (\$38,897 [95% CI: 31,381-48,253] vs. \$15,110 [95% CI: 12,904-17,781]) (Table 4). Moreover, based on the mean total costs, the average costs per patient per year were higher than those of controls (\$3,131 vs. \$1,858, Table 4). Furthermore, the estimated average annual outpatient cost of cases was \$1,791 compared to \$964 for controls (Table 4).

Figure 1 shows the total annual observed mean costs of constipated women and controls according to the year. Overall, cases consistently had higher health care costs between 1987 and 2002, even after adjusting for other comorbid conditions such as abdominal pain and back pain. Figure 2 shows the annual observed outpatient medical costs for constipated

women and controls. Similarly, cases consistently had higher outpatient care costs after adjusting for other comorbid conditions over a 15-year period.

Table 5 summarizes the impact of comorbid conditions on direct medical costs. After adjusting for other comorbid conditions, depression and dyspepsia were all significantly associated with both total and outpatient medical costs. The association of abdominal pain and heartburn/GERD were borderline significantly associated with outpatient medical costs (Table 5). Depression was associated with a 56% increase in total costs and 50% in outpatient medical costs. However, dyspepsia was found to have a decrease in medical costs (-77% in total and -84% in outpatient). Thyroid disorders, anxiety, back pain and headache were not significantly related to direct medical costs (Table 5).

Interactions between co-morbid conditions and constipation were examined for both total medical costs and outpatient medical costs. Only dyspepsia was found to have a significant interaction with constipation status. Among constipated women, patients with dyspepsia were found to have a decrease in both their total (36.7%) and outpatient (55.4%) costs compared to those without dyspepsia. However, women without constipation (controls) had a marginal increase in costs (1.2% and 2.9%, respectively) in patients with dyspepsia versus those without dyspepsia.

Discussion

This is to our knowledge the first population-based longitudinal study to present U.S. data on the costs related with constipation over a 15-year timeframe. We observed that women with a diagnosis of constipation consistently used more of all types of medical services, from outpatient clinics to inpatient hospitalizations and emergency department visits, compared to matched controls. Moreover, women with constipation were more likely to present for abdominal pain or for somatic or psychological co-morbid conditions over a 15-year period. Overall, women with constipation consistently had higher health care costs over time; specifically, the overall annual medical costs for women with constipation are more than twice that of controls.

Constipation is one of the most common digestive disorders in the United States.^{2, 26, 27} Choung et al.²⁷ showed that the cumulative incidence of chronic constipation over 12 years was almost one in six. Moreover, physician office visit related to constipation have dramatically increased.²⁸ Shah et al.²⁸ studied the national trends in physician office visits associated with constipation between 1993 and 2004 using National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Care Survey (NHAMCS) in USA. They showed that ambulatory visits for constipation increased from 4 million (95% CI 3.3–4.7 million) ambulatory visits for constipation annually during 1993–1996 period to 7.95 million (95% CI 6.6–9.4 million) visits during the 2001–2004 period. Not surprisingly, in a recent database analysis by Everhart et al.⁸ on the burden of digestive diseases in the U.S., constipation was the second most common ambulatory care diagnosis after gastroesophageal reflux disease among gastrointestinal diseases. They also showed that hospitalizations for chronic constipation were uncommon. Our study has confirmed these observations; we found a relatively lower number of hospitalizations compared to other medical services and a relatively higher number of outpatient clinic visits. However, all medical services were more frequently used by constipated women. In addition, our study showed that outpatient medical visits for comorbid somatic pain, abdominal pain, and psychological conditions are disproportionately higher for women who present with constipation. This is consistent with other data. Mason et al.²⁹ studied psychological morbidity in women with constipation; they reported that patients with constipation had significantly increased psychological and social morbidity (anxiety, depression, and social

dysfunction) and increased somatization. Other studies have shown that constipation is linked to comorbid conditions, including somatic pain, psychologic conditions, abdominal pain, and other digestive diseases.^{27, 29-31} Thus, it is conceivable that constipation directly and indirectly contributes to high usage of health care resources. Our study showed that women with dyspepsia and constipation actually had lower total (36.7%) and outpatient (55.4%) costs compared to those without dyspepsia, but dyspepsia is unlikely to have had any effects on incremental medical costs because only 14 patients out of 168 constipated women had dyspepsia. Confounding variables might explain less consulting behavior in patients with dyspepsia, such as younger age, although we tried to adjust for confounding.^{32, 33}

Martin et al.³⁴ studied the economic burden of constipation based on an analysis of three national surveys (the 2001 National Ambulatory Medical Care Survey, the 2001 National Hospital Ambulatory Medical Care Survey, and the 2001 National Hospital Discharge Survey). They reported that the costs associated with medical care for constipation totaled \$235 million in 2001.³⁴ This estimate does not include the costs of over-the-counter and prescription drugs or the cost of care when constipation was determined to be a complication of other disease or a comorbid condition. In another study using the California Medicaid program (Medi-Cal), Singh et al.³⁵ showed that constipation-related total Medi-Cal reimbursement over a 15-month period was \$18,891,008, representing a substantial economic loss for the Medicaid system. We obtained data on the incremental medical costs for women with constipation compared to matched controls in longitudinal observations over 15 years. In the current study, the average annual incremental total medical costs over a 15-year period in a woman with constipation was \$1,272 more than controls, and the average annual incremental medical costs of outpatient care in a woman with constipation was \$ 827 more than controls. Because our study compared constipated subjects to controls, it is reasonable to conclude that constipation contributes to significant incremental medical costs.

This study had some potential limitations. First, the study could not include all subjects with constipation in a community, because subjects with symptoms not seeking medical attention would not be identified. Thus, our study likely underestimates the actual direct cost burden of constipation. In this study we were unable to look at indirect costs, such as workday absences or drug use, and thus our cost estimations probably underestimate the impact of the disorder. Moreover, the high medical costs in constipated women might be related to other medical conditions or treatments such as opioid use, surgery, or chemotherapy, etc. However, we still observed higher medical costs in constipated women compared to controls over a 15-year period after adjusting for other comorbid conditions including abdominal pain, depression, and headache. Second, these data are only generalizable to the white U.S. population because the racial composition of this community is predominantly Caucasian.¹⁵ Moreover, the services and the utilization patterns in Olmsted County may not be totally generalizable to other settings due to a higher proportion of the working population being employed in the health care industry and the correspondingly slightly higher education level.

Thus, we conclude from this population-based study that subjects with constipation are greater utilizers of all types of medical services, and this is not explained by comorbid conditions. Interventions to reduce the burden of constipation may be cost saving.

Acknowledgments

The authors wish to thank Lori R. Anderson for her assistance in the preparation of the manuscript.

Grant Support: This investigator initiated study was supported by Takeda Pharmaceuticals, who were not involved in the design, analysis or interpretation of the findings. This study was made possible in part by the Rochester

Epidemiology Project (Grant #R01-AR30582 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases).

References

1. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. *Am J Gastroenterol.* 2001; 96:3130–7. [PubMed: 11721760]
2. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd. Functional constipation and outlet delay: a population-based study. *Gastroenterology.* 1993; 105:781–90. [PubMed: 8359649]
3. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. *Am J Public Health.* 1990; 80:185–9. [PubMed: 2297063]
4. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci.* 1993; 38:1569–80. [PubMed: 8359066]
5. Stewart WF, Liberman JN, Sandler RS, Woods MS, Stenhagen A, Chee E, Lipton RB, Farup CE. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. *Am J Gastroenterol.* 1999; 94:3530–40. [PubMed: 10606315]
6. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. *Am J Gastroenterol.* 2006; 101:2401–9. [PubMed: 17032205]
7. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. *Am J Gastroenterol.* 2004; 99:750–9. [PubMed: 15089911]
8. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. *Gastroenterology.* 2009; 136:741–54. [PubMed: 19166855]
9. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. *Aliment Pharmacol Ther.* 2007; 25:599–608. [PubMed: 17305761]
10. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. *Am J Epidemiol.* 1992; 136:165–77. [PubMed: 1415139]
11. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. *Pharmacoeconomics.* 2005; 23:461–76. [PubMed: 15896098]
12. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. *Dig Dis Sci.* 1989; 34:606–11. [PubMed: 2784759]
13. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol.* 1979; 110:281–90. [PubMed: 474565]
14. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health.* 1997; 6:49–62. [PubMed: 9065374]
15. Melton LJ 3rd. History of the Rochester Epidemiology Project. *Mayo Clin Proc.* 1996; 71:266–74. [PubMed: 8594285]
16. Melton LJ 3rd. The threat to medical-records research. *N Engl J Med.* 1997; 337:1466–70. [PubMed: 9380105]
17. Katusic SK, Colligan RC, Barbaresi WJ, Schaid DJ, Jacobsen SJ. Potential influence of migration bias in birth cohort studies. *Mayo Clin Proc.* 1998; 73:1053–61. [PubMed: 9818038]
18. Chitkara DK, Talley NJ, Weaver AL, Katusic SK, De Schepper H, Rucker MJ, Locke GR 3rd. Incidence of presentation of common functional gastrointestinal disorders in children from birth to 5 years: a cohort study. *Clin Gastroenterol Hepatol.* 2007; 5:186–91. [PubMed: 16901769]
19. Chitkara DK, Talley NJ, Locke GR 3rd, Weaver AL, Katusic SK, De Schepper H, Rucker MJ. Medical presentation of constipation from childhood to early adulthood: a population-based cohort study. *Clin Gastroenterol Hepatol.* 2007; 5:1059–64. [PubMed: 17632040]

20. Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. Predicting the cost of illness: a comparison of alternative models applied to stroke. *Med Decis Making*. 1998; 18:S39–56. [PubMed: 9566466]
21. Choung RS, Shah ND, Chitkara D, Branda ME, Van Tilburg MA, Whitehead WE, Katusic SK, Locke GR 3rd, Talley NJ. Direct Medical Costs of Constipation in Children Older Than 15 Years: A Population-based Birth Cohort. *J Pediatr Gastroenterol Nutr*.
22. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *J Health Econ*. 2001; 20:461–94. [PubMed: 11469231]
23. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. *Qjm*. 1999; 92:177–82. [PubMed: 10326078]
24. Tian L, Huang J. A two-part model for censored medical cost data. *Stat Med*. 2007; 26:4273–92. [PubMed: 17330248]
25. R Development Core Team. R Foundation for Statistical Computing. Vienna, Austria: 2008. R: A language and environment for statistical computing. URL <http://www.R-project.org>, 2008
26. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, Sandler RS. The burden of gastrointestinal and liver diseases, 2006. *Am J Gastroenterol*. 2006; 101:2128–38. [PubMed: 16848807]
27. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988–2003. *Aliment Pharmacol Ther*. 2007; 26:1521–8. [PubMed: 17919271]
28. Shah ND, Chitkara DK, Locke GR, Meek PD, Talley NJ. Ambulatory care for constipation in the United States, 1993–2004. *Am J Gastroenterol*. 2008; 103:1746–53. [PubMed: 18557708]
29. Mason HJ, Serrano-Ikkos E, Kamm MA. Psychological morbidity in women with idiopathic constipation. *Am J Gastroenterol*. 2000; 95:2852–7. [PubMed: 11051359]
30. Talley NJ, Lasch KL, Baum CL. A gap in our understanding: chronic constipation and its comorbid conditions. *Clin Gastroenterol Hepatol*. 2009; 7:9–19. [PubMed: 18829389]
31. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. *Aliment Pharmacol Ther*. 31:938–49. [PubMed: 20180788]
32. Ahlwat SK, Richard Locke G, Weaver AL, Farmer SA, Yawn BP, Talley NJ. Dyspepsia consulters and patterns of management: a population-based study. *Aliment Pharmacol Ther*. 2005; 22:251–9. [PubMed: 16091063]
33. Meineche-Schmidt V, Krag E. Dyspepsia in general practice in Denmark. A 1-year analysis of consulters in general practice *Scand J Prim Health Care*. 1998; 16:216–21.
34. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. *Manag Care Interface*. 2006; 19:43–9. [PubMed: 17274481]
35. Singh G, Lingala V, Wang H, Vadhavkar S, Kahler KH, Mithal A, Triadafilopoulos G. Use of health care resources and cost of care for adults with constipation. *Clin Gastroenterol Hepatol*. 2007; 5:1053–8. [PubMed: 17625982]

Abbreviations

REP	Rochester Epidemiology Project
ICD	International Classification of Diseases
H-ICDA	Hospital Adaptation of the International Classification of Diseases
OCHEUD	Olmsted County Healthcare Expenditure and Utilization Database
U.S.	United States




Figure 1. Mean observed annual total costs for women with constipation versus controls according to year.




Figure 2. Mean observed annual outpatient costs of women with constipation versus controls

Table 1
Medical index for disease (ICD-9 codes)

Disease	ICD-9 codes
GI disease	
GERD or heartburn	530.1, 787.1
Dyspepsia	536.8
Abdominal pain	789.0
Peptic ulcer disease	533. x
Non GI disease	
Headache, tension or migraine	784.0, 307.81, 346, 625.4, 784.0
Thyroid disorder	245, 240.9, 244.2
Diabetes mellitus	250.0
Depression	296.2x, 296.89, 298.0, 300.4, 311
Back pain	724.1, 724.2
Limb pain	729.5, 729.4, 729.5
Anxiety	300.00, 300.02, 300.09, 309.21

GERD=gastroesophageal reflux disease

Table 2
A comparison of sociodemographic characteristics for subjects with constipation versus controls

	Cases N=168	Controls N=336	P-Value
Age of women in 1987, Mean (\pm SD)	33.2 (5.8)	33.2 (5.7)	0.9777
Follow-up years, Mean (\pm SD)	12.6 (2.5)	12.4 (2.6)	0.4079
Non legitimate birth (out of wedlock)	19 (11.3%)	34 (10.1%)	0.6813
Less than 18 at time of birth	6 (3.6%)	13 (3.9%)	0.8687
Maternal education level at child's birth < High School	15 (8.9%)	19 (5.7%)	0.1672
Prenatal visits, Mean (\pm SD)	11.4 (2.6)	11.1 (2.9)	0.2591
Proportion of cesarean delivery	14 (8.3%)	36 (10.7%)	0.3993
Complication of Delivery	64 (38.1%)	138 (41.1%)	0.5204

Table 3
Proportion and Type of Co-morbid Medical Visits in Women with constipation or controls between 1987-2002

	Cases N=168	Controls N=336	P-value
# of non-users (1987-2002 Mayo)	4 (2.4%)	7 (2.1%)	0.8293
# of Patients with an Outpatient Visit(s)	129 (76.8%)	219 (65.2%)	0.0079
# of Patients with a Hospitalization(s)	126 (75.0%)	208 (61.9%)	0.0034
# of Patients with a ER Visit(s)	138 (82.1%)	233 (69.4%)	0.0021
Outpatient visits per patient per year, Mean (\pm SD)	0.17 (0.39)	0.12 (0.34)	<0.0001
Inpatients stays per patient per year, Mean (\pm SD)	0.13 (0.33)	0.09 (0.28)	<0.0001
ER Visits per patient per year, Mean (\pm SD)	0.24 (0.43)	0.15 (0.35)	<0.0001
Comorbidities	142 (84.5%)	223 (66.4%)	<0.0001
GI disease	79 (47.0%)	83 (24.7%)	<0.0001
GERD or heartburn	19 (11.3%)	23 (6.9%)	0.0874
Dyspepsia	14 (8.3%)	20 (6.0%)	0.3151
Abdominal pain	64 (38.1%)	65 (19.4%)	<0.0001
Peptic ulcer disease	4 (2.4%)	3 (0.9%)	0.2291
Non GI disease	136 (81.0%)	214 (63.7%)	<0.0001
Headache, tension or migraine	63 (37.5%)	81 (24.1%)	0.0017
Thyroid disorder	19 (8.3%)	14 (5.7%)	0.2518
Diabetes mellitus	5 (3.0%)	12 (3.6%)	0.7271
Depression	71 (42.3%)	64 (19.1%)	<0.0001
Back pain	88 (52.4%)	105 (31.3%)	<0.0001
Limb pain	97 (57.7%)	116 (34.5%)	<0.0001
Anxiety	39 (23.2%)	37 (11.0%)	0.0003

GERD=Gastroesophageal reflux disease; ER=Emergency Room

Table 4
Estimated Costs of women with constipation versus controls

	Cases N=168	Controls N=336
Total Cost per Patient per Year ¹		
Mean	\$3,130.76	\$1,858.34
Q1-Q3	(1038.87, 3726.77)	(490.83, 2186.12)
Range	(0, 44529.76)	(0, 37879.79)
Outpatient Cost per Patient per Year ¹		
Mean	\$1,791.23	\$963.90
Q1-Q3	(788.94, 2254.25)	(364.41, 1140.20)
Range	(0, 27916.58)	(0, 12170.80)
Inpatient Cost per Patient per Year ¹		
Mean	\$1,294.08	\$863.68
Q1-Q3	(0, 1527.71)	(0, 856.75)
Range	(0, 16369.97)	(0, 36861.19)
Estimated Total Costs (All years) ²	\$63,590.69 (49786.11, 81395.56)	\$24,529.25 (20666.73, 29260.46)
Estimated Outpatient Costs (All years) ²	\$38,897.27 (31380.72, 48253.02)	\$15,109.52 (12904.16, 17780.99)
Estimated total cost at 1990, Mean (95% CI) ^{3, 4}	\$2,162.88 (2094.59, 2239.16)	\$1,765.47 (1727.72, 1810.25)
Estimated total cost at 1995 ^{3, 4}	\$3,545.55 (3295.75, 3821.43)	\$1,550.43 (1476.22, 1630.85)
Estimated total cost at 2000 ^{3, 4}	\$3,171.02 (3008.95, 3350.69)	\$1,718.39 (1652.93, 1784.48)

¹ Unadjusted Cost

² Adjusted by Case vs. Control only.

³ Adjusting for case vs. control, abdominal pain, and back pain

⁴ CI calculating using bootstrap method

Table 5
Multivariable predictors of costs for Cases

Predictor	Outpatient Costs		Total Costs	
	Predicted Change in Costs (%)	P-Value	Predicted Change in Costs (%)	P -Value
Abdominal Pain	28.35	0.09	32.50	0.10
Heartburn/GERD	32.61	0.07	2.30	0.88
Dyspepsia	-84.26	<0.0001	-76.79	0.0009
Depression	50.29	0.008	55.72	0.03
Anxiety	-12.41	0.37	-24.02	0.18
Thyroid	4.02	0.89	-20.23	0.53
Headache	-3.08	0.84	-24.68	0.17
Back Pain	-4.58	0.82	1.34	0.96
Limb Pain	42.35	0.029	17.09	0.50

GERD=Gastroesophageal reflux disease